ABOUT CARDAMYST
The first and only FDA-approved, self-administered prescription treatment for PSVT episodes in adults1,2
CARDAMYST nasal spray is a calcium channel blocker, designed to treat acute symptomatic episodes of PSVT.
Quickly absorbed for peak bioavailability in ~7 minutes, coupled with rapid metabolism1,3
In healthy volunteers, peak concentration of CARDAMYST in the bloodstream was reached at a median of ~7 minutes after a single dose. CARDAMYST was primarily metabolized by blood esterases and the liver, with average concentrations falling by 80% of peak value by 60 minutes.
Delivered a median time to conversion of 17 minutes vs 54 minutes with placebo1
CARDAMYST (etripamil) nasal spray restored sinus rhythm rapidly, more than 3 times faster than placebo.
Empowers patients to be ready anytime, anywhere a PSVT episode occurs1,2*†
CARDAMYST puts control of treating PSVT episodes in patients’ hands.
Patients should administer CARDAMYST in a sitting position and should not exceed 140 mg in 24 hours.1
†Store CARDAMYST at 68 °F to 77 °F (20 °C to 25 °C), with excursions permitted from 59 °F to 86 °F (15 °C to 30 °C).1
More than 1600 patients have taken at least 1 dose of CARDAMYST in the clinical program4‡
‡Includes nonrandomized test dose patients.1,4
Rapid conversion
Review clinical outcomes from the RAPID study.
Profiles of patients with PSVT
Explore hypothetical patient cases and learn more about the impact of PSVT.
Connect with a rep
Get helpful information on CARDAMYST.